In this pooled analysis of the Measure Up 1 and Measure Up 2 studies, adults and adolescents with moderate-to-severe atopic dermatitis who received once-daily upadacitinib (15 or 30 mg) treatment experienced early improvements in symptoms and quality of life.

Within 1–2 weeks of initiating upadacitinib therapy, improvements were observed in patient-reported outcomes measuring itch, pain, other skin symptoms, sleep, daily activities, emotional state, quality of life, impression of disease severity, impression of treatment efficacy, and treatment satisfaction.

Improvements in patient-reported outcomes increased steadily after weeks 1–2 and were maintained through week 52 of upadacitinib treatment.